Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

Roche’s Giredestrant sets new benchmark in early breast cancer treatment

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival

Time Medical launches India’s first low-field TOF MRI for nationwide aneurysm screening

India presents one of the world’s largest untapped opportunities for neurovascular screening

Ingenus Pharma launches first FDA-approved generic version of Premarin

Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk

New England Biolabs unveils high-speed flu sequencing tool to bolster global outbreak surveillance

Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing

XenoTherapeutics to acquire Repare Therapeutics

FDA concludes Lupin’s Nagpur Unit-1 facility inspection with zero observations

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature